Bristol-Myers Squibb Co (NYSE: BMY) on Monday, plunged -0.11% from the previous trading day, before settling in for the closing price of $46.07. Within the past 52 weeks, BMY’s price has moved between $42.52 and $63.33.
The company achieved an average annual earnings per share of 464.12%. With a float of $2.03 billion, this company’s outstanding shares have now reached $2.04 billion.
Bristol-Myers Squibb Co (BMY) Insider and Institutional Ownership
Observing investor behavior towards Drug Manufacturers – General industry stocks is more important than anything else. The insider ownership of Bristol-Myers Squibb Co is 0.06%, while institutional ownership is 82.30%. The most recent insider transaction that took place on Sep 02 ’25, was worth 2,650,480. In this transaction EVP, Chief Financial Officer of this company sold 56,000 shares at a rate of $47.33, taking the stock ownership to the 167,379 shares. Before that another transaction happened on Sep 02 ’25, when Company’s Officer proposed sale 56,000 for $47.30, making the entire transaction worth $2,648,800.
Bristol-Myers Squibb Co (BMY) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported 1.67 earnings per share (EPS) for the period topping the consensus outlook (set at 1.47) by 0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.5 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 464.12% per share during the next fiscal year.
Bristol-Myers Squibb Co (NYSE: BMY) Trading Performance Indicators
Bristol-Myers Squibb Co (BMY) is currently performing well based on its current performance indicators. A quick ratio of 1.17 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.95. Likewise, its price to free cash flow for the trailing twelve months is 6.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.96, a number that is poised to hit 1.61 in the next quarter and is forecasted to reach 6.01 in one year’s time.
Technical Analysis of Bristol-Myers Squibb Co (BMY)
Let’s dig in a bit further. During the last 5-days, its volume was 23.58 million. That was better than the volume of 13.85 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 89.23%.
During the past 100 days, Bristol-Myers Squibb Co’s (BMY) raw stochastic average was set at 42.58%, which indicates a significant decrease from 84.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.92 in the past 14 days, which was lower than the 1.00 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $45.32, while its 200-day Moving Average is $50.16. However, in the short run, Bristol-Myers Squibb Co’s stock first resistance to watch stands at $46.62. Second resistance stands at $47.21. The third major resistance level sits at $47.77. If the price goes on to break the first support level at $45.47, it is likely to go to the next support level at $44.91. The third support level lies at $44.32 if the price breaches the second support level.
Bristol-Myers Squibb Co (NYSE: BMY) Key Stats
Market capitalization of the company is 93.69 billion based on 2,035,436K outstanding shares. Right now, sales total 48,300 M and income totals -8,948 M. The company made 12,269 M in profit during its latest quarter, and 1,311 M in sales during its previous quarter.
